---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-029218"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T21:08:45.361330+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Repligen appoints Martin D. Madaus to board; board expands to 8

## Summary
- Martin Madaus, Ph.D., joined Repligen's board effective Feb 6, 2023, also named to Nominating and Corporate Governance Committee.
- Board size increased from seven to eight directors upon Madaus' election.
- Madaus received initial option grant valued at $170,000, vesting equally over three years.
- Pro-rata equity award of options and RSUs each valued at $21,250, vesting at next annual shareholder meeting.
- Madaus brings over 25 years of life sciences tools industry experience, including CEO roles at Millipore and Ortho Clinical Diagnostics.

## SEC filing metadata
- accession: 0001193125-23-029218
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312523029218/0001193125-23-029218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312523029218/d802605d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-029218
- JSON: https://secwatch.observer/filing/0001193125-23-029218.json
- Plain text: https://secwatch.observer/filing/0001193125-23-029218.txt

## Key facts
- Executive change
  Martin Madaus was elected as Director at REPLIGEN CORP.
  - Action: elected
  - Role: Director
  source text: the Board elected Martin Madaus, Ph.D. to the Board, effective February 6, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/730272/000119312523029218/0001193125-23-029218-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.